The Institute of Cancer Research shared a post on LinkedIn:
“New Research has identified a promising weakness in triple negative Breast Cancer – one of the most aggressive and hardest‑to‑treat forms of the disease.
Scientists at the ICR, funded by Breast Cancer Now, have uncovered how the gene HORMAD1, usually active only in reproductive cells, becomes switched on in around 60 per cent of triple negative breast cancers and disrupts a key safety mechanism in cell division.
Crucially, this flaw can be targeted. The team identified existing cancer drugs – including Aurora B, MPS1 and BUB1 inhibitors – that can block this process in the lab, with Aurora B inhibitors also reducing tumor growth.
With around 8,000 UK women diagnosed with triple negative breast cancer each year, these findings mark an important step toward developing more precise treatments.
Study author Professor Andrew Tutt, Director of the Breast Cancer Now Toby Robins Research Centre at The Institute of Cancer Research, London, and The Breast Cancer Now Research Unit at King’s College London London, says:
‘Although this research is still in its early stages, it offers an important step forward in understanding triple negative breast cancer and opens the door for the development of new treatments.’
Other articles about Breast Cancer on OncoDaily.